# Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

> **NCT03226444** · PHASE1,PHASE2 · COMPLETED · sponsor: **TearSolutions, Inc.** · enrollment: 204 (actual)

## Conditions studied

- Primary Sjögren Syndrome
- Dry Eye

## Interventions

- **DRUG:** 0.005% Lacripep
- **DRUG:** 0.01% Lacripep
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03226444
- **Lead sponsor:** TearSolutions, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-30
- **Primary completion:** 2019-12-27
- **Final completion:** 2019-12-27
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226444, "Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03226444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*